Global Immuno-Oncology Cell Therapy Market Size is valued at USD 11.9 Billion in 2024 and is predicted to reach USD 95.3 Billion by the year 2034 at a 23.2% CAGR during the forecast period for 2025-2034.

Immuno-oncology cell therapies are a remarkably promising treatment for a different types of cancer patients. The approval of CAR-T cell therapy products represents one of the most significant breakthroughs in cancer since the introduction of chemotherapy. Immuno-oncology cell therapies are one of the fastest advancing technology along with huge research and development activities. The oncology market today could be quickly superseded by next generation therapies in the upcoming forecast period. The Immuno-oncology Cell Therapy market is driven by factors such as increasing research funding in the immune-oncology, rising prevalence of cancer and focus on research activities from government health institutions and pharma giants inImmuno-oncology therapy development.
The global immuno-oncology cell therapies market is classified based on therapy type and region. Based on the therapy type, the market is segmented into CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies.Geographically, the Americas dominate the immuno-oncology cell therapies market owing to high healthcare expenditure and the rise in awareness among people. Europe stands for the second position in the immuno-oncology cell therapies market. It is expected that the support provided by government bodies for research & development and increased clinical trial programs in healthcare is going to drive the market in the Europe region. The Asia Pacific is known to be the fastest-growing immuno-oncology cell therapies market leading to a huge patient pool, developing healthcare technology and improving healthcare expenditure. The Middle East & Africa has the lowest market for immuno-oncology cell therapies due to inadequate medical facilities and lack of technical knowledge.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 11.93 Billion |
| Revenue Forecast In 2034 | USD 95.3 Billion |
| Growth Rate CAGR | CAGR of 23.2% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Therapy Type, By Indication Type, By Cell Source |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Novartis, Juno Therapeutics, Agios Pharmaceutical, Atara Biotherapeutics, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio, Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, Editas Medicine, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm, JW Therapeutics, Medigene, MedisixTherapeutics, Lion TCR, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, Posedia Therapeutics, Zelluna Immunotherapy, and others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Therapy Type

Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Major Indication
By Cell Source
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Region
Europe Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
North America Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
Asia Pacific Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
Latin America Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
Middle East & Africa Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.